Pharmacokinetics of bupropion and its metabolites in haemodialysis patients who smoke: A single dose study

Nephron - Clinical Practice

Volumn 97, Issue 3, 2004, Pages

  Worrall, Simon P R ^a,c   Almond, Michael K ^a   Dhillon, Soraya ^b  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF LONDON   (United Kingdom)

^c Department of Oncology   (United Kingdom)

Author keywords

Bupropion; Haemodialysis; Hydroxybupropion; Metabolites; Pharmacokinetics; Threohydrobupropion

Indexed keywords

AMFEBUTAMONE; DRUG METABOLITE; HYDROXYBUPROPION; THREO HYDROBUPROPION; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; FEMALE; HEMODIALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; REGRESSION ANALYSIS; SMOKING HABIT; SUSTAINED DRUG RELEASE;

ADULT; AGED; ARYL HYDROCARBON HYDROXYLASES; BIOTRANSFORMATION; BUPROPION; COHORT STUDIES; CYTOCHROME P-450 CYP2D6; DRUG INTERACTIONS; FEMALE; HUMANS; KIDNEY; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; OXIDOREDUCTASES, N-DEMETHYLATING; RENAL DIALYSIS; SMOKING; SMOKING CESSATION;

EID: 4043171420     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000078635     Document Type: Article

References (24)

1. Royal College of Physicians: Nicotine Addiction in Britain: A Report of the Tobacco Advisory Group of the Royal College of Physicians. London, Royal College of Physicians, February 2000.
2. Foley RN, Herzog CA, Collins AJ: Smoking and cardiovascular outcomes in dialysis patients: The United States Renal Data System Wave 2 Study. Kidney Int 2003;63:1462-1467.
3. Aubin HJ: Tolerability and safety of sustainedrelease bupropion in the management of smoking cessation. Drugs 2002;62:45-52.
4. Aronoff GR, et al: Drug Prescribing in Renal Failure - Dosing Guidelines for Adults, ed 4. Washington, American College of Physicians, 1999, p 92.
5. Sweet RA, Pollock BG, Kirshner M, Wright B, Altieri LP, DeVane CL: Pharmacokinetics of single- and multiple-dose bupropion in elderly patients with depression. J Clin Pharmacol 1995;35:876-884.
6. DeVane CL, Laizure SC, Cameron DF: The effect of experimentally-induced renal failure on accumulation of bupropion and its major basic metabolites in plasma and brain of guinea pigs. Psychopharmacology (Berl) 1986;89:404-408.
7. Kaka JS, Al-Khamis KI, Tanira MO: Effect of hepatic and renal dysfunction on disposition of bupropion in rats. Eur J Drug Metab Pharmacokinet 1988;13:149-153.
8. Golden RN, DeVane CL, Laizure SC, Rudorfer MV, Sherer MA, Potter WZ: Bupropion in depression. II. The role of metabolites in clinical outcome. Arch Gen Psychiatry 1988;45:145-149.
9. Martin P, Massol J, Colin JN, Lacomblez L, Puech AJ: Antidepressant profile of bupropion and three metabolites in mice. Pharmacopsychiatry 1990;23:187-194.
10. Sanchez C, Hyttel J: Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell Mol Neurobiol 1999;19:467-489.
11. Laizure SC, DeVane CL: Stability of bupropion and its major metabolites in human plasma. Ther Drug Monit 1985;7:447-450.
12. Hsyu PH, Singh A, Giargiari TD, Dunn JA, Ascher JA, Johnston JA: Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers. J Clin Pharmacol 1997;37:737-743.
13. Findlay JW, Van Wyck Fleet J, Smith PG, Butz RF, Hinton ML, Blum MR, Schroeder DH: Pharmacokinetics of bupropion, a novel antidepressant agent, following oral administration to healthy subjects. Eur J Clin Pharmacol 1981;21:127-135.
14. Laizure SC, DeVane CL, Stewart JT, Dommisse CS, Lai AA: Pharmacokinetics of bupropion and its major basic metabolites in normal subjects after a single dose. Clin Pharmacol Ther 1985;38:586-589.
15. Lai AA, Schroeder DH: Clinical pharmacokinetics of bupropion: A review. J Clin Psychiatry 1983;44:82-84.
16. Posner J, Bye A, Jeal S, Peck AW, Whiteman P: Alcohol and bupropion pharmacokinetics in healthy male volunteers. Eur J Clin Pharmacol 1984;26:627-630.
17. Preskorn SH: Should bupropion dosage be adjusted upon therapeutic drug monitoring? Psychopharmacol Bull 1991;27:637-643.
18. Goodnick PJ: Pharmacokinetic optimisation of therapy with newer antidepressants. Clin Pharmacokinet 1994;27:307-330.
19. Preskorn SH: Antidepressant response and plasma concentrations of bupropion. J Clin Psychiatry 1983;44:137-139.
20. Fogel P, Mamer OA, Chouinard G, Farrell PG: Determination of plasma bupropion and its relationship to therapeutic effect. Biomed Mass Spectrom 1984;11:629-632.
21. Goodnick PJ: Blood levels and acute response to bupropion. Am J Psychiatry 1992;149:399-400.
22. Storrow AB: Bupropion overdose and seizure. Am J Med 1994;12:183-184.
23. Harris CR, Gualtieri J, Stark G: Fatal bupropion overdose. J Toxicol Clin Toxicol 1997;35: 321-324.
24. Stewart JJ, Berkel HJ, Parish RC, Simar MR, Syed A, Bocchini JA Jr, Wilson JT, Manno JE: Single-dose pharmacokinetics of bupropion in adolescents: Effects of smoking status and gender. J Clin Pharmacol 2001;41:770-778.